Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 13 of 13

List	Outcome	Time frame	Description
Primary	Proportion of Participants Reporting Smoking Cessation at Week 6	At baseline, immediately after the six-week intervention (Week 6)	Smoking cessation status will be assessed by participant self-report. The outcome is the proportion of participants who report having stopped smoking cigarettes at Week 6, compared between the intervention and control groups.
Primary	Change in Stage of Change for Smoking Cessation from Baseline to Week 6	Baseline and Week 6	Stage of change will be assessed using the Stage of Change Questionnaire based on the Transtheoretical Model. Participants will be classified into precontemplation, contemplation, preparation, action, or maintenance. Change in stage from baseline to Week 6 will be evaluated and compared between the intervention and control groups.
Primary	Proportion of Participants Reporting Smoking Cessation at 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	The proportion of participants who report having stopped smoking 3 months after completion of the 6-week intervention.
Primary	Change in Stage of Change for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 months after completion of the 6-week intervention	Change in participants' stage of change for smoking cessation, classified as precontemplation, contemplation, preparation, action, or maintenance, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Smoking Cessation Self-Efficacy from Baseline to Week 6	Baseline and Week 6	Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to the end of the 6-week intervention period.
Secondary	Change in Smoking Cessation Self-Efficacy from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Decisional Balance for Smoking Cessation from Baseline to Week 6	Baseline and Week 6	Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to Week 6.
Secondary	Change in Decisional Balance for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Cigarette Craving Scores from Baseline to Week 6	Baseline and Week 6	Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to Week 6.
Secondary	Change in Cigarette Craving Scores from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Nicotine Dependence Scores from Baseline to Week 6	Baseline and Week 6	Change in participants' nicotine dependence scores, measured using the Fagerström Test for Nicotine Dependence (FTND), from baseline to Week 6.
Secondary	Change in Nicotine Dependence Scores from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' nicotine dependence scores, measured using the Fagerström Test for Nicotine Dependence (FTND), from baseline to 3 months after completion of the 6-week intervention.
Secondary	Participant Satisfaction with the Chatbot Intervention	Week 6	Participants' satisfaction with the chatbot intervention will be assessed using a 5-point rating question ranging from 1 (not at all satisfied) to 5 (very satisfied). Participants' likelihood of recommending the intervention to a friend will be assessed using a rating scale ranging from 0 (not at all likely) to 10 (extremely likely).

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07887217/registered

API reference For AI assistants